Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy

分享:

简介:

  • 作者: Christiano R. R. Alves, Leillani L. Ha, Rebecca Yaworski, Emma R. Sutton, Cicera R. Lazzarotto, Kathleen A. Christie, Aoife Reilly, Ariane Beauvais, Roman M. Doll, Demitri de la Cruz, Casey A. Maguire, Kathryn J. Swoboda, Shengdar Q. Tsai, Rashmi Kothary & Benjamin P. Kleinstiver
  • 杂志: Nature Biomedical Engineering
  • Doi: https://www.doi.org/10.1038/s41551-023-01132-z
  • 出版日期: 2023 Dec 6

论文中使用的产品/服务

Quotation shows PackGene:For genome editing experiments, two AAV9 vectors encoding ABE8e-SpRY split into N- and C-terminal fragments via an Npu intein (as described above and similar to a previous report68) paired with gRNA A8 were packaged by PackGene Biotech.

Research Field:spinal muscular atrophy

AAV Serotype:AAV9

Targeted organ:Spinal muscle

Animal or cell line strain:mice

询价

摘要

Spinal muscular atrophy (SMA) is caused by mutations in SMN1. SMN2 is a paralogous gene with a C•G-to-T•A transition in exon 7, which causes this exon to be skipped in most SMN2 transcripts, and results in low levels of the protein survival motor neuron (SMN). Here we show, in fibroblasts derived from patients with SMA and in a mouse model of SMA that, irrespective of the mutations in SMN1, adenosine base editors can be optimized to target the SMN2 exon-7 mutation or nearby regulatory elements to restore the normal expression of SMN. After optimizing and testing more than 100 guide RNAs and base editors, and leveraging Cas9 variants with high editing fidelity that are tolerant of different protospacer-adjacent motifs, we achieved the reversion of the exon-7 mutation via an A•T-to-G•C edit in up to 99% of fibroblasts, with concomitant increases in the levels of the SMN2 exon-7 transcript and of SMN. Targeting the SMN2 exon-7 mutation via base editing or other CRISPR-based methods may provide long-lasting outcomes to patients with SMA.

关于派真

作为一家专注于AAV 技术十余年,深耕基因治疗领域的CRO&CDMO,派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付,我们为全球客户提供一站式CMC解决方案,包括从早期概念验证、成药性评估到IITINDBLA的各个阶段。

 

凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台,我们能将AAV产量提高多至10倍,每批次产量可达1×10¹⁷vg,以满足多样化的商业化和临床项目需求。此外,我们定制化的mRNA和脂质纳米颗粒(LNP)产品及服务覆盖药物和疫苗开发的各个阶段,从研发到符合GMP的生产,提供端到端的一站式解决方案。

下载